Skip to main content
search

catalent

By April 15, 2019Headlines

Catalent, which offers comprehensive drug development and commercialization services, is acquiring Paragon Bioservices for $1.2 billion, adding expertise in manufacturing gene therapies.

https://www.wsj.com/articles/contract-drug-manufacturer-catalent-to-buy-paragon-bioservices-in-1-2-billion-deal-11555277951

Tags:

Related Posts

Headlines
February 6, 2024

Cano

Cano Health apparently cannot, as it declares bankruptcy due to too much debt.  Building primary…
Kevin Roche 0
Headlines
January 24, 2024

Turquoise

Turquoise health raises a fresh $30 million in capital for its price transparency platform, as…
Kevin Roche 0
Headlines
January 24, 2024

CAR-T safety

I am co-f0under of a company that manages cell and gene therapy for health plans.…
Kevin Roche 0

Leave a comment

Close Menu